Persevere Therapeutics Inc.
- Biotech or pharma, therapeutic R&D
Persevere Therapeutics Inc is an oncology newco launched in February 2025 to acquire the rights to a clinical stage program (misetionamide - GP-2250) from Geistlich Pharma and their subsidiary, Panavance Therapeutics. Investors will have a unique opportunity to leverage the significant $40 million invested to date including a broad preclinical program and a successful Phase 1 clinical trial in the development of misetionamide. Persevere is pursuing an initial capital raise of $13 million to finance completion of a Phase 1b proof of concept clinical trial in platinum-resistant ovarian cancer (PROC). An IND for this indication was filed in late February with the FDA to conduct this trial.
Address
ChesterbrookPennsylvania
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}